Form 4: Tonix Pharmaceuticals Director Receives Stock Option Grant

Adeoye Y. Olukotun, a director at Tonix Pharmaceuticals, was granted a stock option for 10,000 shares on May 13, 2025.

Summary

• On May 13, 2025, Adeoye Y. Olukotun, a director of Tonix Pharmaceuticals Holding Corp., received a stock option for 10,000 shares.
• The option has an exercise price of $20.18.
• The option vests on the earlier of the one-year anniversary of the grant date (May 13, 2026) or the Issuer's 2026 Annual Meeting of Stockholders.
• The option expires on May 13, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

NA

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize stock options as part of their compensation strategy to attract and retain talent.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director, potentially benefiting the company's employees and other stakeholders.

Key Dates

Keywords

stock option, director, TNXP, Tonix Pharmaceuticals, beneficial ownership, Form 4